We are a clinical stage ophthalmology company that is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions worldwide. We have a broad product candidate portfolio of multiple technologies in the preclinical and clinical development stages intended to provide solutions to ophthalmic disorders affecting millions of people worldwide. We are pursuing development of our product candidates for debilitating diseases such as diabetic retinopathy/diabetic macular edema, cataract, retinitis pigmentosa, Stargardt disease, and age-related macular degeneration. As part of our mobile Health application initiatives, we are also developing technologies intended to detect nascent disease progression to improve treatment outcome in patients with wet age-related macular degeneration, diabetic macular edema and other neovascular retinal diseases.
Company profile
Ticker
KBBTF
Exchange
Website
CEO
Ryo Kubota
Employees
Location
Fiscal year end
Industry (SIC)
Former names
Acucela Inc, Acucela Inc.
SEC CIK
Corporate docs
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
11 Dec 17
POS AM
Prospectus update (post-effective amendment)
7 Dec 17
S-8 POS
Registration of securities for employees (post-effective amendment)
7 Dec 17
15F-12G
Securities registration termination (foreign)
6 Dec 17
6-K
Current report (foreign)
9 Nov 17
6-K
Current report (foreign)
8 Aug 17
8-K
Other Events
26 Jul 17
8-K
Submission of Matters to a Vote of Security Holders
26 May 17
8-K
Entry into a Material Definitive Agreement
25 May 17
10-Q
2017 Q1
Quarterly report
10 May 17